Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175373 | 1.00 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTPER2CRY1 | |
| SCHEMBL21127002 | 0.94 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTKMT2APKM | |
| SCHEMBL23969731 | 0.82 | LMNA (0.47) | ALDH1A1LMNAMAPTKMT2APKM | |
| SCHEMBL10145306 | 0.78 | LMNA (0.38) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL15865805 | 0.78 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTKMT2AGAA | |
| SCHEMBL26243113 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTPER2CRY1 | |
| SCHEMBL81620 | 0.75 | ALDH1A1 (0.39) | ALDH1A1LMNAKMT2APKMPOLB | |
| SCHEMBL22519832 | 0.75 | KMT2A (0.36) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL23841443 | 0.75 | ALDH1A1 (0.39) | ALDH1A1LMNAKMT2APKMPOLB | |
| SCHEMBL12236665 | 0.75 | ALDH1A1 (0.39) | ALDH1A1LMNAKMT2APKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | ALDH1A1 1025/4885LMNA 2184/4885MAPT 3667/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | ALDH1A1 1025/4885LMNA 2184/4885MAPT 3667/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | ALDH1A1 1025/4885LMNA 2184/4885MAPT 3667/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | ALDH1A1 2563/4885LMNA 547/4885MAPT 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.